<b id="309tb"></b>

      <video id="309tb"><center id="309tb"></center></video><u id="309tb"></u>
      About Kingfriend
      Kingfriend Overview

      Nanjing Kingfriend integrates drug research and development, production and sales.

      Listed on SSE A share on 19th July, 2017, Kingfriend has, not only the world’s leading isolator production line and advanced aseptic injection production technology, but also a globalized quality system, approved by many countries and regions, including China, the United States, Europe, Japan and Brazil, etc. With a world-class production research and development speed and the globalized quality awareness, we have the sales capability that make us take root in the U.S. market. Besides, injectable CDMO service, covering the global market while targeting at China and US markets’, can be provided by us. By attracting and recruiting talents from all over the globe, our newly established bio-innovative pharmaceuticals business department aims at becoming an innovative and international biopharmaceutical company that is superior in pharmaceutical field.
      • 50+
      • 10+
      • 3times
      • 10+
      • 10+
      Total ANDA approvals
      New ANDA approvals obtained each year
      FDA-compliant high-speed isolator production line
      Annual declaration of products to FDA
      Cumulative number of FDA inspection passed
      The Global Industry Layout

      We establish efficient, integrated and open project management systems for global pharmaceutical companies

      • Nanjing Headquarter

        R&D Center
        Development, production and commercial manufacturing of small molecule injectables
        Drug development and commercialization based on mRNA technology
        Treatment based on nucleic acid detection technology (mRNA)
        Bioinformatics determination of target molecules
        platform for mRNA in vitro synthesis and modification
        Drug delivery system development
      • Cheng Du

        R&D center
        Hydro-acupuncture and lyophilization product line
        Monoclonal antibody-based drugs (mAb)
        Early research and development of monoclonal antibody
        Commercial development monoclonal antibodies
      • Chicago, USA

        Global Clinical Research Center
        U.S. Marketing
      Milestones

      Over the past 30 years, we have been refreshing our goals and making positive progress.

      2022
      57 ANDA approvals obtained in total
      pipeline expansion at a rate of 10 new projects per year
      2021
      Establishment of Bio-innovative Business Department
      Improved R&D capabilities and entered the field of biologics
      2019
      Acquisition of US pharmaceutical company Meitheal
      Broadened the global market of preparations and completed the coverage of the industry chain
      2016
      Acquisition of Chengdu Jianjin Pharmaceutical
      Full set of FDA-compliant GMP workshop
      audited by the FDA
      2014
      Passed CFDA GMP inspection
      Obtained three domestic approvals and started filling with ANDA
      2011
      Construction of Nanjing FDF plant started
      The world’s top FDF plant
      2004
      Launch of enoxaparin, nadroparin and dalteparin preparation projects
      Initiated the development and declaration of heparin-based APIs and preparations
      2000
      Establishment of Nanjing Kingfriend Biochemical Pharmaceutical Co, Ltd
      Ventured into pharmaceutical export business
      1991
      Establishment of Nanjing Kingfriend Chemical Biopharmaceutical Factory
      Rapid development in heparin industry
      1987
      Involvement in the field of heparin sodium
      Pioneer in the heparin industry in China
      2022
      2021
      2019
      2016
      2014
      2011
      2004
      2000
      1991
      1987
      Enterprise Honors

      Our employees, who are enterprising and innovative, have obtained a number of remarkable achievements.

      • Awarded the title of Nanjing Outstanding Private Enterprise and Entrepreneur
        2018
        Awarded the title of Nanjing Outstanding Private Enterprise and Entrepreneur
      • Nanjing Municipal Key Leading Enterprise of Agricultural Industrialization
        2022
        Nanjing Municipal Key Leading Enterprise of Agricultural Industrialization
      • Outstanding Company of Open Economy of Jiangsu Province
        2012
        Outstanding Company of Open Economy of Jiangsu Province
      • Enterprise Technology Center recognized by Jiangsu Province
        2022
        Enterprise Technology Center recognized by Jiangsu Province
      • Enterprise Technology Center recognized by Jiangsu Province
        2014
        Enterprise Technology Center recognized by Jiangsu Province
      • National-level High-tech Enterprise Certificate
        2018
        National-level High-tech Enterprise Certificate
      • Awarded the title of Nanjing Smart Factory
        2015
        Awarded the title of Nanjing Smart Factory
      • Private Technology Enterprise Certificate
        2017
        Private Technology Enterprise Certificate
      More honors
      无码人妻精品一区二区三区久久r_国产午夜亚洲精品午夜鲁丝片_久久久久久久久免费看无码_亚洲午夜精品久久久久久人妖

      <b id="309tb"></b>

          <video id="309tb"><center id="309tb"></center></video><u id="309tb"></u>